2020 Androgenetic Alopecia - Pipeline Insight - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Androgenetic Alopecia - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the androgenetic alopecia market. A detailed picture of the androgenetic alopecia pipeline landscape is provided, which includes the disease overview and androgenetic alopecia treatment guidelines.

The assessment part of the report embraces in-depth androgenetic alopecia commercial assessment and clinical assessment of the androgenetic alopecia pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, androgenetic alopecia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for androgenetic alopecia.
• in the coming years, the androgenetic alopecia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence androgenetic alopecia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the androgenetic alopecia treatment market. Several potential therapies for androgenetic alopecia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the androgenetic alopecia market size in the coming years.
• The in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of androgenetic alopecia ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

• What are the current options for androgenetic alopecia treatment?
• How many companies are developing therapies for the treatment of androgenetic alopecia?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for the treatment of androgenetic alopecia?
• How many androgenetic alopecia emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of androgenetic alopecia?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
• What are the key collaborations (industry-industry, industry-academia), mergers and acquisitions, and major licensing activities that will impact androgenetic alopecia market?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of androgenetic alopecia?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing androgenetic alopecia therapies?
• What are the clinical studies going on for androgenetic alopecia and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for androgenetic alopecia?
• How many patents are granted and pending for the emerging therapies for the treatment of androgenetic alopecia?

Key Topics Covered:

1. Report Introduction

2. Androgenetic Alopecia

2.1. Overview

2.2. History

2.3. Androgenetic Alopecia Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Androgenetic Alopecia Diagnosis

2.6.1. Diagnostic Guidelines

3. Androgenetic Alopecia Current Treatment Patterns

3.1. Androgenetic Alopecia Treatment Guidelines

4. Androgenetic Alopecia - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Androgenetic Alopecia companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Androgenetic Alopecia Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Androgenetic Alopecia Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Androgenetic Alopecia Late Stage Products (Phase-III)

7. Androgenetic Alopecia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Androgenetic Alopecia Discontinued Products

13. Androgenetic Alopecia Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Androgenetic Alopecia Key Companies

15. Androgenetic Alopecia Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Androgenetic Alopecia Unmet Needs

18. Androgenetic Alopecia Future Perspectives

19. Androgenetic Alopecia Analyst Review

20. Appendix

21. Report Methodology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bqh1ju